Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 3,500 shares of Protagonist Therapeutics stock in a transaction on Monday, March 12th. The shares were sold at an average price of $21.29, for a total value of $74,515.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ PTGX traded down $0.13 during mid-day trading on Friday, hitting $8.78. 299,231 shares of the stock traded hands, compared to its average volume of 421,691. Protagonist Therapeutics Inc has a twelve month low of $7.85 and a twelve month high of $23.97. The company has a market cap of $188.04, a price-to-earnings ratio of -4.20 and a beta of 3.56.
Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Wednesday, March 7th. The company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.19. The firm had revenue of $11.28 million for the quarter, compared to analyst estimates of $8.75 million. equities research analysts anticipate that Protagonist Therapeutics Inc will post -0.66 EPS for the current year.
Several equities analysts have recently issued reports on the company. Stifel Nicolaus lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 26th. BMO Capital Markets reiterated an “outperform” rating and issued a $42.00 price target (down previously from $44.00) on shares of Protagonist Therapeutics in a research note on Thursday, March 8th. Zacks Investment Research upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research note on Tuesday, March 13th. Finally, BidaskClub lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $26.75.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PTGX. Farallon Capital Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at $18,720,000. First Manhattan Co. boosted its holdings in shares of Protagonist Therapeutics by 2,408.2% during the 4th quarter. First Manhattan Co. now owns 416,364 shares of the company’s stock valued at $8,660,000 after acquiring an additional 399,764 shares in the last quarter. BVF Inc. IL acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at $6,118,000. AWM Investment Company Inc. acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at $3,686,000. Finally, Jennison Associates LLC acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at $2,080,000. 56.08% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Protagonist Therapeutics Inc (NASDAQ:PTGX) Insider Sells 3,500 Shares of Stock” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/protagonist-therapeutics-inc-ptgx-insider-sells-74515-00-in-stock.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.